Evidence map›Paper›PMID 32256353›Full record

ArticleFrontiers in pharmacology2020

Structure-Based Screening of

Emilee E Colón-Lorenzo, Daisy D Colón-López, Joel Vega-Rodríguez, Alice Dupin, David A Fidock, Abel Baerga-Ortiz, José G Ortiz, Jürgen Bosch, Adelfa E Serrano

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Revisiting Glutathione Transferases ofPharmaceuticals (Basel, Switzerland) · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Targeting theHeliyon · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Emilee E Colón-LorenzoDepartment of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, PR, United States.
Daisy D Colón-LópezDepartment of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Joel Vega-RodríguezDepartment of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, PR, United States.
Alice DupinDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY, United States.
David A FidockDepartment of Microbiology and Immunology, Columbia University Medical Center, New York, NY, United States.
Abel Baerga-OrtizDepartment of Biochemistry, University of Puerto Rico School of Medicine, San Juan, PR, United States.
José G OrtizDepartment of Pharmacology and Toxicology, University of Puerto Rico School of Medicine, San Juan, PR, United States.
Jürgen BoschDepartment of Biochemistry and Molecular Biology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
Adelfa E SerranoDepartment of Microbiology and Medical Zoology, University of Puerto Rico School of Medicine, San Juan, PR, United States.
University of Puerto Rico, Medical Sciences Campus · PRColumbia University Irving Medical Center · USUniversity of Puerto Rico System · PRIntralytix (United States) · USJohns Hopkins University · US

Funding

Upstream Regulation and Downstream effectors of c-MYC in Ovarian CancerU54MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI Abiel Roche-Lima · 2017 to 2026
$35.8M
UPR--MEDICAL SCIENCES CAMPUS, MBRS PROGRAMS06GM008224 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI SILVA, WALTER I · 1989 to 2008
$28.0M
RISE Option III: MBRS RISE at the UPR Medical Sciences CampusR25GM061838 · NIGMS · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI CADILLA, CARMEN LYDIA · 2000 to 2021
$25.5M
TRANSLATIONAL PROTEOMICS CENTERG12MD007600 · NIMHD · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FERNANDEZ-REPOLLET, EMMA · 2012 to 2016
$11.0M
Host-parasite-vector interactions during malaria transmissionZIAAI001250 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI VEGA-RODRIGUEZ, JOEL · 2019 to 2025
$9.9M
Role of pfcrt in chloroquine resistance in P. falciparumR01AI050234 · NIAID · YESHIVA UNIVERSITY · PI FIDOCK, DAVID A · 2001 to 2015
$5.7M
Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4M
NIAID NIH HHS R01 AI050234NIAID NIH HHS R37 AI050234NIGMS NIH HHS R25 GM061838NIGMS NIH HHS S06 GM008224NIMHD NIH HHS G12 MD007600NIMHD NIH HHS U54 MD007600
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antimalarial drug discoverydrug targetglutathione S-transferasemalariaPlasmodium bergheipredicted pharmacokinetic and toxicity parametersshape similarity screeningstructure-based screening

Identifiers

PMID32256353
PMCPMC7090221
OpenAlexW3012192521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.